VEGFA and age-related macular degeneration: In the last decade, anti-angiogenic therapy, i.e., intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, has been the standard of care for the treatment of neovascular eye diseases, particularly in age-related macular degeneration (AMD), diabetic retinopathy (DR) including diabetic macular edema (DME), and macular edema secondary to retinal vein occlusions (RVO).